Book Volume 4
Page: i-i (1)
Page: ii-ii (1)
Page: 1-33 (33)
Author: Sesha S. Alluri and Ashit K. Ganguly
Human immunodeficiency virus (HIV-1) protease inhibitors play an important role as a part of the HAART (Highly Active Antiretroviral Therapy) treatment regimen for AIDS infection. The main cellular target for HIV-1 is helper Tlymphocytes that is critical to the immune system and renders individuals susceptible to opportunistic infections and tumors. According to World Health Organization, globally 36.9 million people are living with HIV-1 at the end of 2017 making HIV-1 a prime target for drug discovery.
HIV-1 belongs to the family ‘retroviridae’ that characteristically carry their genetic information in the form of ribonucleic acid (RNA). There are several drug targets that interfere with the life cycle of HIV-1 virus. Drugs such as enfuvirtide inhibit the entry of HIV-1 into the cell by interacting with CD4 receptors and co-receptors CCR5/CXCR4. Three key enzymes involved in the survival and replication of virus inside the host cell are reverse transcriptase, integrase, and protease. Once inside the host, the viral enzyme reverse transcriptase converts the viral RNA into proviral DNA. Azido thymidine (AZT) was the first reverse transcriptase inhibitor discovered. In the next step of viral replication, the proviral DNA is inserted into the host cell genome by the viral enzyme, HIV-1 integrase. Integrase inhibitors (e.g. raltegravir) block this step. Following integration, viral transcription factors cause the normal cellular machinery to produce multiple copies of viral m-RNA, which is transported from the nucleus back into the cytoplasm. In the cytoplasm, viral core proteins are produced as long chain polypeptides that are cleaved by the viral HIV-1 protease enzyme, into smaller polypeptides in order to become functional. HIV-1 protease inhibitors block this step and are considered as major breakthrough in AIDS research. Although there are several drug classes that inhibit the life cycle of HIV-1 virus at various stages, the major emphasis of this chapter will be on the discovery of linear sulfonamides such as darunavir which in particular is being very successfully used in the clinic. We shall also summarize the discovery from our laboratory of a novel class of cyclic sulfonamides as potent HIV-1 protease inhibitors.
The HIV-1 protease inhibitors represent one of the classic examples of structure-based drug design. The X-ray crystal structure of HIV-1 protease was determined in 1989 and several inhibitors were soon developed based on the configuration of the active site. Protease inhibitors such as saquinavir, ritonavir, indinavir, amprenavir, tipranavir, darunavir etc., are successfully used for the treatment of AIDS patients. Today, new protease inhibitors are continuously being developed and designed because HIV-1 virus mutates quickly, and current medications are becoming increasingly ineffective.
In our published work, we have successfully discovered a novel class of HIV-1 protease inhibitors based on a cyclic sulfonamide core structure. HIV-1 protease inhibitors in clinical use such as amprenavir, tipranavir and darunavir possess sulfonamide moiety in their core structure. Unlike open chain sulfonamides used in the clinic, our compounds possess a conformationally restricted sulfonamide pharmacophore. Molecular modeling was used for the design of these inhibitors and the crucial step in their synthesis involved an unusual endo radical cyclization process.
Several analogs were synthesized in order to determine their structure activity relationship. X-ray crystallographic analysis confirmed the binding modes of our inhibitors to the HIV-1 protease enzyme. The structures of the novel inhibitors were further optimized to the picomolar affinities in the HIV-1 protease assay. More work remains to be done to determine whether these cyclic sulfonamides could be clinically useful.
Page: 34-60 (27)
Author: Vidya Sagar, Arti Vashist and Madhavan Nair
The human immunodeficiency virus (HIV) infection into the brain induces neurotoxicity and neuropathology which are collectively termed as the neuroAIDS. Brain delivery of therapeutic molecules continues to be the greatest challenge, primarily because of the tightly-junctioned blood-brain barrier (BBB). Several nanovehicles are under intensive examination for delivering drugs across the BBB. Magnetic nanoparticles (MNPs) possess advantages over their counterparts because of their potential utilization for non-invasive brain targeting using external magnetic force. MNPs can be physicochemically modulated for engineering smart drug delivery carrier as well. Nonetheless, rigorous research is required to fix associated shortcomings of MNPs before their real-time application.
Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing
Page: 61-104 (44)
Author: Omobolanle Janet Jesumoroti, Faith Akwi and Paul Watts
A number of new antiviral drugs have made HIV/AIDS a manageable disease by the introduction of integrase strand transfer inhibitors. One of the major concerns is the accessibility of these drugs in lower income countries. Thus, adequate supplies and cost effective syntheses of these drugs via flow technology are of great importance. Presently, there are four integrase strand transfer inhibitors approved by FDA. This chapter will focus on the published synthesis of currently FDA approved integrase inhibitor drugs and other HIV drugs developed through flow technology. Thus hoping that such a review could be useful to scientists and academia desiring a greater understanding of HIV integrase drug development at reduced cost and could serve as a context for further research and possible collaboration with the industry.
Page: 105-137 (33)
Author: Yi-Qun Kuang
Entry of HIV-1 into targeted host cells is a highly ordered multistage process involving first-receptor attachment, co-receptor binding, and membrane fusion. In this chapter, I will present an overview of progress on HIV-1 entry inhibitors with a focus on chemokine receptor-based antagonists. This chapter, at first, will describe the working mechanisms of chemokine receptors, HIV-1 co-receptors CCR5 and CXCR4, during the replication procedure. Then, the antagonists-based on different mechanisms will be presented in detail. At last, it will summarize and explain the distinct promising entry inhibitors based on co-receptors-interacting proteins, which is inspired by our current work.
Page: 138-152 (15)
Author: Ana Paula Ferreira Costa, Marcos Gonzaga dos Santos and Ricardo Ney Oliveira Cobucci
Sexually transmitted co-infections increase HIV infectiousness through local inflammatory processes. The risk factors in acquiring genital co-infections associated with HIV infection still present many questions. There is some evidence that there is an association between certain sexually transmitted infections and HIV, but for others, there is only a marginal correlation, as will be discussed in this chapter. The most prevalent co-infections found in HIV carriers and their epidemiology, clinical features and evidence-based treatments will also be analyzed.
Page: 153-157 (5)
Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the book series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research. </p> <p> The fourth volume of this series features 5 chapters that cover these topics: </p> <p> - Design and Synthesis of HIV-1 Protease Inhibitors </p> <p> - Potential Magnetic Nanotherapeutics for Management of neuroAIDS </p> <p> - Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing </p> <p> - The Development and Clinical Progress on Chemokine Receptor-Based HIV Entry Inhibitors </p> <p> - Sexually Transmitted Co-infections in Persons Living with HIV </p>